Identification

Name
Artemether
Accession Number
DB06697
Type
Small Molecule
Groups
Approved
Description

Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.

Structure
Thumb
Synonyms
  • (1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
  • 10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
  • Artemetero
  • Artemetherum
  • Artemisininelactol methyl ether
  • beta-Artemether
  • beta-Dihydroartemisinin methyl ether
  • Dihydroartemisinin methyl ether
  • Dihydroqinghaosu methyl ether
  • Methyl-dihydroartemisinine
  • SM-224
External IDs
SM 224
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CoartemArtemether (20 mg/1) + Lumefantrine (120 mg/1)TabletOralDepartment Of State Health Services, Pharmacy Branch2009-04-072018-02-28Us
CoartemArtemether (20 mg/1) + Lumefantrine (120 mg/1)TabletOralNovartis2009-04-07Not applicableUs00078 0568 45 nlmimage10 6c443641
CoartemArtemether (20 mg/1) + Lumefantrine (120 mg/1)TabletOralCentral Texas Community Health Centers2009-04-07Not applicableUs
Categories
UNII
C7D6T3H22J
CAS number
71963-77-4
Weight
Average: 298.3746
Monoisotopic: 298.178023942
Chemical Formula
C16H26O5
InChI Key
SXYIRMFQILZOAM-HVNFFKDJSA-N
InChI
InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
IUPAC Name
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecane
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4

Pharmacology

Indication

Artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.

Associated Conditions
Pharmacodynamics

In the body, artemether is metabolized into the active metabolite metabolite dihydroartemisinin. The drug works against the erythrocytic stages of P. falciparum by inhibiting nucleic acid and protein synthesis. Artemether is administered in combination with lumefantrine for improved efficacy. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thought that artemether provides rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.

Mechanism of action

Involves an interaction with ferriprotoporphyrin IX (“heme”), or ferrous ions, in the acidic parasite food vacuole, which results in the generation of cytotoxic radical species.

The generally accepted mechanism of action of peroxide antimalarials involves interaction of the peroxide-containing drug with heme, a hemoglobin degradation byproduct, derived from proteolysis of hemoglobin. This interaction is believed to result in the formation of a range of potentially toxic oxygen and carbon-centered radicals.

Absorption

Food increases absorption.

Volume of distribution
Not Available
Protein binding

Artemether and lumefantrine are both highly bound to human serum proteins in vitro (95.4% and 99.7%, respectively). Dihydroartemisinin is also bound to human serum proteins (47% to 76%).

Metabolism

Rapidly metablized to its active metabolite, dihydroartemisinin.

Route of elimination
Not Available
Half life

Artemether, 1.6 +/- 0.7 and 2.2 +/- 1.9 hr; Dihydroartemisinin, 1.6 +/- 0.6 and 2.2 +/- 1.5 hr

Clearance
Not Available
Toxicity

Animal studies on acute toxicity show that the LD50 of Artemether in mice is a single i.g. administration of 895mg/kg and a single i.m. injection of 296mg/kg dose; in rats, the LD50 is a single i.m. injection of 597mg/kg dose.

Affected organisms
  • Plasmodium
Pathways
PathwayCategory
Artemether Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Artemether.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of QTc prolongation can be increased when 5'-Deoxy-5'-Methylthioadenosine is combined with Artemether.Experimental
AbirateroneThe serum concentration of Artemether can be increased when it is combined with Abiraterone.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Artemether.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Artemether.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Artemether.Approved
Acetyl sulfisoxazoleThe metabolism of Artemether can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Artemether.Approved
AgmatineThe therapeutic efficacy of Artemether can be increased when used in combination with Agmatine.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Artemether.Approved, Investigational
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Artemether.Approved, Vet Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Artemether.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Artemether.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Artemether.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Artemether.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Artemether.Approved, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Artemether.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Artemether.Approved
AmlodipineThe therapeutic efficacy of Artemether can be increased when used in combination with Amlodipine.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Artemether.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Artemether.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Artemether.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Artemether.Approved, Investigational
AmrinoneThe therapeutic efficacy of Artemether can be increased when used in combination with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Artemether.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Artemether.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Artemether.Approved, Investigational
ApalutamideThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Apalutamide resulting in a loss in efficacy.Approved, Investigational
ApalutamideThe serum concentration of Artemether can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AprepitantThe serum concentration of Artemether can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Artemether.Approved
AranidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Aranidipine.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Artemether.Approved, Investigational
ArmodafinilThe metabolism of Artemether can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Artemether.Approved, Investigational
ArtemisininThe risk or severity of QTc prolongation can be increased when Artemisinin is combined with Artemether.Investigational
ArtemotilThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Artemether.Approved
ArtenimolThe risk or severity of QTc prolongation can be increased when Artenimol is combined with Artemether.Approved, Investigational
ArtesunateThe risk or severity of QTc prolongation can be increased when Artesunate is combined with Artemether.Approved, Investigational
AsenapineThe risk or severity of QTc prolongation can be increased when Asenapine is combined with Artemether.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Artemether.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Artemether.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Artemether can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Artemether.Approved
AtovaquoneThe risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Artemether.Approved
AzelnidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Artemether can be increased when used in combination with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Artemether.Approved
BarnidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Artemether.Approved
BencyclaneThe therapeutic efficacy of Artemether can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Benidipine.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Artemether.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Artemether.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Artemether.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Artemether.Approved, Investigational
BioallethrinThe therapeutic efficacy of Artemether can be increased when used in combination with Bioallethrin.Approved, Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Artemether.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Artemether.Investigational
BoceprevirThe metabolism of Artemether can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
BosentanThe serum concentration of Artemether can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Artemether.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Artemether.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Artemether.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Artemether.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Artemether.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Artemether can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Artemether.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Artemether.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Artemether.Approved
CapecitabineThe metabolism of Artemether can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Artemether.Approved
CarbamazepineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
CarbamazepineThe metabolism of Artemether can be increased when combined with Carbamazepine.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Artemether can be increased when used in combination with Carboxyamidotriazole.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Artemether.Approved, Investigational
CaroverineThe therapeutic efficacy of Artemether can be increased when used in combination with Caroverine.Experimental
CarteololThe metabolism of Carteolol can be decreased when combined with Artemether.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Artemether.Approved, Investigational
CelecoxibThe metabolism of Artemether can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Artemether can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Artemether.Approved
ChloramphenicolThe metabolism of Artemether can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Artemether.Approved, Illicit, Investigational
ChlormadinoneThe serum concentration of Chlormadinone can be decreased when it is combined with Artemether.Experimental
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Artemether.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Artemether.Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Artemether.Experimental
ChlorproguanilThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Artemether.Investigational
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Artemether.Approved
CholecalciferolThe metabolism of Artemether can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Artemether.Approved, Investigational
CimetidineThe metabolism of Artemether can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Artemether can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Artemether.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Artemether.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Artemether.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Artemether.Approved
ClemastineThe metabolism of Artemether can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Artemether.Approved, Investigational
ClobazamThe metabolism of Artemether can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Artemether.Approved
ClopidogrelThe metabolism of Artemether can be decreased when combined with Clopidogrel.Approved
ClotrimazoleThe metabolism of Artemether can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Artemether.Approved
CobicistatThe serum concentration of Artemether can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Artemether can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Artemether.Approved, Investigational
CrisaboroleThe metabolism of Artemether can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Artemether.Approved
CurcuminThe metabolism of Artemether can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe therapeutic efficacy of Artemether can be increased when used in combination with Cyclandelate.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.Approved
Cycloguanil embonateThe risk or severity of QTc prolongation can be increased when Cycloguanil embonate is combined with Artemether.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Artemether.Approved, Investigational
DabrafenibThe serum concentration of Artemether can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Artemether.Approved
DapsoneThe risk or severity of QTc prolongation can be increased when Dapsone is combined with Artemether.Approved, Investigational
DarifenacinThe metabolism of Artemether can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe therapeutic efficacy of Artemether can be increased when used in combination with Darodipine.Experimental
DarunavirThe serum concentration of Artemether can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Artemether.Approved
DasatinibThe serum concentration of Artemether can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Artemether.Approved, Investigational
DeferasiroxThe serum concentration of Artemether can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Artemether.Approved
DelavirdineThe metabolism of Artemether can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Artemether.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Artemether.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Artemether.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Artemether.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Artemether.Approved, Illicit, Investigational, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Artemether.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Artemether.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Artemether.Approved
DidanosineDidanosine can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Artemether.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Artemether.Approved, Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.Approved, Illicit
DihydroergotamineThe metabolism of Artemether can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Artemether can be decreased when combined with Diltiazem.Approved, Investigational
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Artemether.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Artemether.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Artemether.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Artemether.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Artemether.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Artemether.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Artemether.Approved
DosulepinThe metabolism of Artemether can be decreased when combined with Dosulepin.Approved
DotarizineThe therapeutic efficacy of Artemether can be increased when used in combination with Dotarizine.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Artemether.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Artemether.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Artemether.Approved, Investigational
DoxycyclineThe risk or severity of QTc prolongation can be increased when Doxycycline is combined with Artemether.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Artemether.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Artemether.Approved
DuloxetineThe metabolism of Artemether can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Artemether.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Artemether.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Artemether.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Artemether.Investigational
EnzalutamideThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.Approved
EnzalutamideThe serum concentration of Artemether can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe therapeutic efficacy of Artemether can be increased when used in combination with Eperisone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Artemether.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Artemether.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Artemether.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Artemether can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Artemether.Investigational
EsomeprazoleThe metabolism of Artemether can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Artemether.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Artemether.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Artemether.Approved, Investigational, Vet Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether.Approved
EthosuximideThe therapeutic efficacy of Artemether can be increased when used in combination with Ethosuximide.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Artemether.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Artemether.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Artemether.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Artemether.Approved, Investigational
EtravirineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Etravirine resulting in a loss in efficacy.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Artemether.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Artemether.Approved
FelodipineThe therapeutic efficacy of Artemether can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Artemether can be increased when used in combination with Fendiline.Withdrawn
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Artemether.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Artemether.Approved, Investigational
Fish oilThe therapeutic efficacy of Artemether can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Artemether.Approved, Withdrawn
FloxuridineThe metabolism of Artemether can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Artemether can be decreased when combined with Fluconazole.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Artemether.Approved
FluorouracilThe metabolism of Artemether can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Artemether.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Artemether.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.Approved
FluspirileneThe therapeutic efficacy of Artemether can be increased when used in combination with Fluspirilene.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Artemether.Approved
FluvoxamineThe metabolism of Artemether can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
FosamprenavirThe metabolism of Artemether can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Artemether can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Artemether.Approved
FosphenytoinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.Approved, Investigational
FosphenytoinThe serum concentration of Artemether can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Artemether can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe therapeutic efficacy of Artemether can be increased when used in combination with Gabapentin.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Artemether.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Artemether.Approved
GallopamilThe therapeutic efficacy of Artemether can be increased when used in combination with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Artemether.Approved, Investigational
GemfibrozilThe metabolism of Artemether can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Artemether.Approved, Investigational
GestrinoneThe serum concentration of Gestrinone can be decreased when it is combined with Artemether.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Artemether.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Artemether.Approved, Investigational
HalofantrineThe risk or severity of QTc prolongation can be increased when Halofantrine is combined with Artemether.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Artemether.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Artemether.Approved, Vet Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Artemether.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Artemether.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Artemether.Approved, Illicit
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether.Approved
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Artemether.Approved, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Artemether.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Artemether.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Artemether.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Artemether.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Artemether.Approved
IdelalisibThe metabolism of Artemether can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Artemether.Approved
ImatinibThe metabolism of Artemether can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Artemether.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Artemether.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Artemether.Approved
IndinavirThe metabolism of Artemether can be decreased when combined with Indinavir.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Artemether.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.Approved
IrbesartanThe metabolism of Artemether can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Artemether can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Artemether can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
IsoniazidThe metabolism of Artemether can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineIsradipine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
ItraconazoleThe metabolism of Artemether can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineArtemether may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Artemether can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Artemether.Approved, Investigational
KetoconazoleThe metabolism of Artemether can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Artemether.Approved
LacidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Artemether can be increased when used in combination with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LeflunomideThe metabolism of Artemether can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LercanidipineThe therapeutic efficacy of Artemether can be increased when used in combination with Lercanidipine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Artemether.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Artemether can be increased when used in combination with Levetiracetam.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Artemether.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Artemether.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Artemether.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Artemether.Approved, Vet Approved
LidoflazineThe therapeutic efficacy of Artemether can be increased when used in combination with Lidoflazine.Experimental
LisurideThe metabolism of Lisuride can be decreased when combined with Artemether.Approved, Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Artemether.Experimental
LobeglitazoneThe metabolism of Artemether can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe metabolism of Lofexidine can be decreased when combined with Artemether.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Artemether.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Artemether.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Artemether.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Artemether.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Artemether.Approved
LorpiprazoleThe serum concentration of Artemether can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Artemether.Approved
LovastatinThe metabolism of Artemether can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Artemether can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Lumacaftor resulting in a loss in efficacy.Approved
LumacaftorThe serum concentration of Artemether can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Artemether.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Artemether.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Artemether can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Artemether can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Artemether.Approved, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Artemether.Approved, Investigational
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Artemether.Approved, Investigational
Megestrol acetateThe serum concentration of Megestrol acetate can be decreased when it is combined with Artemether.Approved, Investigational, Vet Approved
MentholThe therapeutic efficacy of Artemether can be increased when used in combination with Menthol.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Artemether.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Artemether.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Artemether.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Artemether.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Artemether.Approved, Illicit
MethotrimeprazineThe metabolism of Artemether can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
MethsuximideThe therapeutic efficacy of Artemether can be increased when used in combination with Methsuximide.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Artemether.Approved, Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Artemether.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Artemether.Approved, Illicit, Withdrawn
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Artemether.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Artemether.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Artemether.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Artemether.Approved, Investigational
MibefradilThe therapeutic efficacy of Artemether can be increased when used in combination with Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Artemether can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneArtemether may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Artemether.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Artemether.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Artemether.Approved
MitotaneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Mitotane resulting in a loss in efficacy.Approved
MitotaneThe serum concentration of Artemether can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Artemether.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Artemether.Approved, Investigational
ModafinilThe metabolism of Artemether can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Artemether.Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Artemether.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Artemether.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
NabiloneThe metabolism of Artemether can be decreased when combined with Nabilone.Approved, Investigational
NaftopidilThe therapeutic efficacy of Artemether can be increased when used in combination with Naftopidil.Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Artemether.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Artemether.Approved, Investigational
NefazodoneThe metabolism of Artemether can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Artemether can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Artemether can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Nevirapine resulting in a loss in efficacy.Approved
NevirapineThe serum concentration of Artemether can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Artemether can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Artemether.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Artemether.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Artemether.Approved
NiguldipineThe therapeutic efficacy of Artemether can be increased when used in combination with Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Artemether.Approved, Investigational
NiludipineThe therapeutic efficacy of Artemether can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Artemether can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Artemether can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Artemether can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Artemether can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Artemether can be increased when used in combination with Nitrendipine.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
Nomegestrol acetateThe serum concentration of Nomegestrol acetate can be decreased when it is combined with Artemether.Approved, Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Artemether.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Artemether.Approved
NorethynodrelThe serum concentration of Norethynodrel can be decreased when it is combined with Artemether.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Artemether.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Artemether.Approved, Investigational
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Artemether.Approved
NorgestrienoneThe serum concentration of Norgestrienone can be decreased when it is combined with Artemether.Experimental
NortriptylineNortriptyline may increase the QTc-prolonging activities of Artemether.Approved
NylidrinThe therapeutic efficacy of Artemether can be increased when used in combination with Nylidrin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Artemether.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
OlaparibThe metabolism of Artemether can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Artemether.Approved
OmeprazoleThe metabolism of Artemether can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Artemether.Approved
OpiumThe metabolism of Opium can be decreased when combined with Artemether.Approved, Illicit
OsimertinibThe serum concentration of Artemether can be increased when it is combined with Osimertinib.Approved
OtiloniumThe therapeutic efficacy of Artemether can be increased when used in combination with Otilonium.Experimental, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Artemether.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
PalbociclibThe serum concentration of Artemether can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Artemether.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Artemether.Approved, Investigational
PanobinostatThe serum concentration of Artemether can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Artemether can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Artemether can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Artemether.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Artemether.Approved
Peginterferon alfa-2bThe serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
PentobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Pentobarbital resulting in a loss in efficacy.Approved, Investigational, Vet Approved
PentobarbitalThe metabolism of Artemether can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Artemether.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Artemether.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Artemether.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Artemether.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Artemether.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Artemether.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Artemether.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.Approved, Investigational
PhenobarbitalThe metabolism of Artemether can be increased when combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenytoin resulting in a loss in efficacy.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Artemether.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Artemether.Approved
PinaveriumThe therapeutic efficacy of Artemether can be increased when used in combination with Pinaverium.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Artemether.Approved, Investigational
PiperaquineThe risk or severity of QTc prolongation can be increased when Piperaquine is combined with Artemether.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Artemether.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Artemether.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Artemether.Approved, Investigational
PonatinibThe metabolism of Ponatinib can be decreased when combined with Artemether.Approved, Investigational
PosaconazoleThe metabolism of Artemether can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrenylamineThe therapeutic efficacy of Artemether can be increased when used in combination with Prenylamine.Withdrawn
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Artemether.Approved
PrimidoneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Primidone resulting in a loss in efficacy.Approved, Vet Approved
PrimidoneThe metabolism of Artemether can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Artemether.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Artemether.Approved, Vet Approved
ProgesteroneThe absorption of Progesterone can be decreased when combined with Artemether.Approved, Vet Approved
ProguanilThe risk or severity of QTc prolongation can be increased when Proguanil is combined with Artemether.Approved
PromazinePromazine may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
PropafenoneThe serum concentration of Artemether can be increased when it is combined with Propafenone.Approved
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Artemether.Approved, Investigational
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Artemether.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Artemether.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Artemether.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Artemether.Approved
PyrimethamineThe risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether.Approved, Investigational, Vet Approved
PyronaridineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Artemether.Investigational
QuazepamThe serum concentration of Artemether can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Artemether.Approved
QuinacrineThe risk or severity of QTc prolongation can be increased when Quinacrine is combined with Artemether.Approved, Investigational
QuingestanolThe serum concentration of Quingestanol can be decreased when it is combined with Artemether.Experimental
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Artemether.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether.Approved
RadicicolThe risk or severity of QTc prolongation can be increased when Radicicol is combined with Artemether.Experimental
RanitidineThe metabolism of Ranitidine can be decreased when combined with Artemether.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Artemether.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Artemether.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Artemether.Investigational
RifabutinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifabutin resulting in a loss in efficacy.Approved, Investigational
RifabutinThe metabolism of Artemether can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifampicin resulting in a loss in efficacy.Approved
RifampicinThe metabolism of Artemether can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifapentine resulting in a loss in efficacy.Approved, Investigational
RifapentineThe metabolism of Artemether can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Artemether.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Artemether.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
RitonavirThe metabolism of Artemether can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Artemether can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Artemether can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Artemether.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Artemether.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Artemether.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Artemether.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Artemether.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Artemether.Approved, Investigational
SarilumabThe therapeutic efficacy of Artemether can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Artemether.Approved
SecobarbitalThe metabolism of Artemether can be increased when combined with Secobarbital.Approved, Vet Approved
SeletracetamThe therapeutic efficacy of Artemether can be increased when used in combination with Seletracetam.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Artemether.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SildenafilThe metabolism of Artemether can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Artemether can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Artemether can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Artemether.Approved
SinefunginThe risk or severity of QTc prolongation can be increased when Sinefungin is combined with Artemether.Experimental
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Artemether.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Artemether.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Artemether.Experimental
St. John's WortThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with St. John's Wort resulting in a loss in efficacy.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Artemether can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe metabolism of Artemether can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfadoxineThe risk or severity of QTc prolongation can be increased when Sulfadoxine is combined with Artemether.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Artemether.Approved
SulfametopyrazineThe risk or severity of QTc prolongation can be increased when Sulfametopyrazine is combined with Artemether.Approved, Withdrawn
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Artemether.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Artemether.Approved, Investigational
TafenoquineThe risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Artemether.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Artemether resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Artemether.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Artemether.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Artemether.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Artemether can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Artemether.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Artemether.Approved
TerbinafineThe metabolism of Artemether can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Artemether.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Artemether.Approved, Withdrawn
TerodilineThe therapeutic efficacy of Artemether can be increased when used in combination with Terodiline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Artemether.Investigational
TetrabenazineThe risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Artemether.Approved, Investigational
TetrahydropalmatineThe therapeutic efficacy of Artemether can be increased when used in combination with Tetrahydropalmatine.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Artemether.Approved
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Artemether.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Artemether.Withdrawn
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Artemether.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Artemether.Approved, Withdrawn
ThiotepaThe metabolism of Artemether can be decreased when combined with Thiotepa.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Artemether.Approved
TicagrelorThe metabolism of Artemether can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Artemether can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Artemether.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Artemether.Approved
TipranavirThe metabolism of Artemether can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TocilizumabThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Artemether can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Artemether can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TopiramateThe metabolism of Artemether can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Artemether can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Artemether.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Artemether.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.Approved, Investigational
TranilastThe therapeutic efficacy of Artemether can be increased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Artemether can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.Approved, Investigational
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.Approved, Vet Approved
TrimebutineThe therapeutic efficacy of Artemether can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Artemether can be increased when used in combination with Trimethadione.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Artemether.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Artemether.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Artemether.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Artemether.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Artemether.Approved, Investigational
Valproic AcidThe metabolism of Artemether can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Artemether can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Vandetanib is combined with Artemether.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Artemether.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemether.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Artemether.Approved
VerapamilThe metabolism of Artemether can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Artemether.Approved, Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Artemether.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Artemether.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Artemether.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Artemether.Approved, Investigational
VinpocetineThe therapeutic efficacy of Artemether can be increased when used in combination with Vinpocetine.Investigational
VoriconazoleThe metabolism of Artemether can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Artemether.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Artemether.Approved, Investigational
WIN 55212-2The therapeutic efficacy of Artemether can be increased when used in combination with WIN 55212-2.Experimental
YohimbineThe metabolism of Yohimbine can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Artemether can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Artemether.Approved, Investigational
ZiconotideThe therapeutic efficacy of Artemether can be increased when used in combination with Ziconotide.Approved
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Artemether.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Artemether.Approved
ZonisamideThe therapeutic efficacy of Artemether can be increased when used in combination with Zonisamide.Approved, Investigational
ZucapsaicinThe metabolism of Artemether can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Artemether.Approved, Investigational
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of artemether and lumefantrine.

References

Synthesis Reference

Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. Pubmed.

General References
  1. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5. doi: 10.1186/1475-2875-8-S1-S5. [PubMed:19818172]
  2. Mutabingwa TK, Adam I: Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther. 2013 Feb;11(2):125-35. doi: 10.1586/eri.12.169. [PubMed:23409819]
  3. Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. [PubMed:8053018]
External Links
Human Metabolome Database
HMDB0015643
KEGG Drug
D02483
PubChem Compound
68911
PubChem Substance
99443251
ChemSpider
62138
BindingDB
50022886
ChEBI
195280
ChEMBL
CHEMBL566534
PharmGKB
PA165111698
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Artemether
ATC Codes
P01BF01 — Artemether and lumefantrineP01BE02 — Artemether
FDA label
Download (1.73 MB)
MSDS
Download (566 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionPlasmodium Infections1
1CompletedNot AvailableHealthy Volunteers / Plasmodium Infections1
1CompletedHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedTreatmentMalaria caused by Plasmodium falciparum1
1CompletedTreatmentMalaria caused by plasmodium vivax1
1RecruitingPreventionPlasmodium Infections1
1, 2RecruitingTreatmentTumors, Solid1
2Active Not RecruitingTreatmentPlasmodium Infections1
2CompletedTreatmentMalaria caused by Plasmodium falciparum1
2Not Yet RecruitingTreatmentPlasmodium Infections1
2RecruitingTreatmentAcute Uncomplicated Plasmodium Falciparum Malaria1
2RecruitingTreatmentPlasmodium Infections1
3Active Not RecruitingTreatmentPlasmodium Falciparum Infection1
3CompletedTreatmentMalaria caused by plasmodium vivax1
3CompletedTreatmentMalaria in Pregnancy1
3CompletedTreatmentPlasmodium Falciparum Malaria2
3CompletedTreatmentPlasmodium Infections11
3Unknown StatusTreatmentPlasmodium Infections1
4CompletedNot AvailablePlasmodium Infections1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
4CompletedBasic SciencePlasmodium Falciparum Clinical Episode / Plasmodium Falciparum Infection / Plasmodium Vivax Clinical Episode / Plasmodium Vivax Infection1
4CompletedHealth Services ResearchAnemias / Plasmodium Infections / Pregnancy1
4CompletedOtherPlasmodium Infections1
4CompletedTreatmentFalciparum / Plasmodium Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Plasmodium Infections1
4CompletedTreatmentInstantaneous Clearance1
4CompletedTreatmentMalaria caused by Plasmodium falciparum4
4CompletedTreatmentParasitologically Confirmed; Malarial1
4CompletedTreatmentPlasmodium Falciparum Malaria1
4CompletedTreatmentPlasmodium Infections9
4RecruitingTreatmentUncomplicated Plasmodium Falciparum Malaria1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4TerminatedTreatmentMalaria caused by Plasmodium falciparum1
4TerminatedTreatmentPlasmodium Infections1
4TerminatedTreatmentPlasmodium Vivax Malaria1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4Unknown StatusTreatmentPlasmodium Infections2
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
4Unknown StatusTreatmentUncomplicated Malaria1
Not AvailableCompletedNot AvailableUncomplicated Malaria1
Not AvailableCompletedHealth Services ResearchPlasmodium Infections / Pneumonia1
Not AvailableCompletedOtherPlasmodium Infections1
Not AvailableCompletedTreatmentMalaria caused by Plasmodium falciparum1
Not AvailableCompletedTreatmentNon-malarial Febrile Illness / Plasmodium Infections1
Not AvailableCompletedTreatmentPlasmodium Infections2
Not AvailableCompletedTreatmentPlasmodium Infections / Pneumonia1
Not AvailableCompletedTreatmentUncomplicated Malaria2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)86-90Not Available
water solubilityInsoluble # http://www.rxlist.com/coartem-drug.htm
logP3.53AVERY,MA ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP3.02ALOGPS
logP3.48ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.15 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability32.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9012
Blood Brain Barrier+0.9393
Caco-2 permeable+0.7876
P-glycoprotein substrateSubstrate0.6031
P-glycoprotein inhibitor IInhibitor0.8918
P-glycoprotein inhibitor IINon-inhibitor0.7056
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8665
CYP450 2D6 substrateSubstrate0.5341
CYP450 3A4 substrateSubstrate0.7023
CYP450 1A2 substrateInhibitor0.6829
CYP450 2C9 inhibitorNon-inhibitor0.9413
CYP450 2D6 inhibitorNon-inhibitor0.9474
CYP450 2C19 inhibitorNon-inhibitor0.8733
CYP450 3A4 inhibitorNon-inhibitor0.9434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9672
Ames testNon AMES toxic0.7285
CarcinogenicityNon-carcinogens0.9179
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.2114 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.7601
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.86 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0950000000-2ae4d4c9200a42ec883d

Taxonomy

Description
This compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Sesquiterpenoids
Direct Parent
Artemisinins
Alternative Parents
Oxepanes / Trioxanes / Oxanes / Dialkyl peroxides / Oxacyclic compounds / Acetals / Hydrocarbon derivatives
Substituents
Artemisinin skeleton / Oxepane / 1,2,4-trioxane / Oxane / Dialkyl peroxide / Oxacycle / Organoheterocyclic compound / Acetal / Organic oxygen compound / Hydrocarbon derivative
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
semisynthetic derivative, sesquiterpenoid, artemisinin derivative, cyclic acetal, organic peroxide (CHEBI:195280)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on May 05, 2010 12:03 / Updated on July 02, 2018 18:34